First FDA-approved treatment for Alexander disease

Ionis has received FDA approval for the first treatment targeting Alexander disease, an ultra-rare neurological disorder. This marks the first FDA-approved intervention for patients with this conditio

Ionis has received FDA approval for the first treatment targeting Alexander disease, an ultra-rare neurological disorder. This marks the first FDA-approved intervention for patients with this condition. While the treatment addresses a critical need for a specific patient group, Alexander disease affects fewer than 10 people globally. The approval establishes a pathway for future rare disease therapies but remains limited in scale due to the disorder’s rarity. Source unreachable; full clinical data and patient impact details sit with the original reporting.

Source: Fierce Biotech